跳至主要内容
临床试验/JPRN-UMIN000024025
JPRN-UMIN000024025招募中未知

The clinical impact of methotrexate dose reduction at combination therapy with adalimumab plus methotrexate in rheumatoid arthritis; ALIBABA study - ALIBABA study

Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare0 个研究点目标入组 80 人开始时间: 2016年10月1日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. An autoimmune disease patient except RA which can affect the inflammatory views 2. The patient receiving the following treatments within four weeks before baseline The increase of glucocorticoid (GC) dosage or newly administration of GC 3. Plasma pheresis 4. The surgical management that it is thought to affect the efficacy evaluation 5. The patient who uses GC more than 5 mg a day 6. A patient with a history of administration of ADA 7. A patient (less than two weeks before therapeutic drug dosage start) less than number of the lymphocytes 1,000 per micro litter 8. The patient with severe infectious diseases 9. A pregnant or nursing woman, the woman who may be pregnant, the woman in hope of the pregnancy and the partner 10. The patient who participates in the clinical trials such as similar effect therapeutic drugs now

研究者

发起方
Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare

相似试验